New Anticancer Medications- Pharmacist

  Price  

  Credits  2

This product is currently out of stock and unavailable.


Format
In 2013 there were 27 new molecular entities approved and 10 were for the treatment of cancer. This reflects the trend in recent years for approval of a disproportionate number of oncology drugs compared with non-oncology drugs. The trend may be a byproduct of the FDA Modernization Act of 1997, which provides for easier drug approval for conditions with unmet medical needs. It allows for a fast track process including an expedited 6 month New Drug Application review that requires only one high quality study for approval. Adding to the faster approval process is the fact that research data submitted for oncology drugs are often less rigorous than for other drugs (e.g., studies with smaller sample size, often with no blinding and/or no control group, and a lower level of statistical significance). Currently, FDA approval of oncology drugs is based on clinical studies that involve the site of the cancer (eg, breast cancer, lung cancer). This may change in the future because scientists now understand that the behavior of a cancer – and how it responds to treatment – are dependent on the molecular pathways that drive cancer cell growth, rather than the location of the cancer in the body. The new cancer czar Richard Pazdur has suggested that the FDA approval process for future oncology drugs be based on studies targeting specific malfunctioning molecular growth pathways, rather than the site of the cancer. This issue reviews oncology drugs by cancer site as is still the standard, covering 6 recently approved agents for the 4 most common cancers: lung, prostate, breast, and colorectal cancer. The drugs' role in therapy, side effects, and (for oral agents) pertinent patient counseling points are summarized. Selected drug interactions are listed in Table 1. Table 2 summarizes key information for 11 additional new agents. Community providers can facilitate access to these very expensive new drugs by helping patients identify assistance programs and/or clinical trials.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-14-003-H04-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.